IP Library Granted Patent US 9,744,341
Granted Patent B2
US 9,744,341 · App. 13/742,203 · Granted Aug 29, 2017

Devices and methods for intraluminal retention and drug delivery

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,744,341
App. No.
13/742,203
Granted
Aug 29, 2017
Kind
B2
Abstract

Retention devices and methods are provided for drug delivery. The device may include a housing configured for intraluminal deployment into a human or animal subject and at least one reservoir contained within the housing. The at least one reservoir may have an actuation end and a release end and contain at least one drug formulation. A plug may be contained within the at least one reservoir and be moveable from the actuation end toward the release end. The device may also include an actuation system operably connected to the actuation end of the at least one reservoir and configured to drive the at least one drug formulation from the reservoir. The device may also include at least one retention member affixed to the housing and movable between a non-stressed position, a deployment position, and a retention position for retaining the device in an intraluminal location in the subject.

Claims (15)

1. A device for drug delivery comprising:

a housing configured for intravaginal or intrauterine deployment into a human or animal subject;

at least one reservoir contained within the housing, the at least one reservoir having an actuation end and a release end and containing at least one drug formulation;

a plug within the at least one reservoir and moveable from the actuation end toward the release end;

an actuation system operably connected to the actuation end of the at least one reservoir and configured to drive the plug and displace the at least one drug formulation from the reservoir; and

at least one retention member affixed to the housing and movable between a non-stressed position, a deployment position, and a retention position for retaining the device in an intravaginal or intrauterine location in the subject, wherein the at least one retention member comprises a spiral member having a first end and a second end, the first end being affixed to the housing and the second end being distal to the housing, wherein the spiral member comprises a central axis about which the spiral member turns, and wherein the first end is affixed to the housing such that the central axis is parallel to a longitudinal axis of the housing.

2. The device of claim 1 , wherein the at least one retention member is in substantially the same position in the deployment position and in the retention position.

3. The device of claim 1 , wherein the device is configured to be deployed in a vaginal or uterine lumen of the human or animal subject by twisting the device such that the spiral member exerts a spring force against walls of the vaginal or uterine lumen in the retention position.

4. The device of claim 1 , wherein the spiral member is configured to be straightened in the deployment position.

5. The device of claim 1 , wherein the spiral member is configured such that a twisting motion of the device facilitates insertion and removal of the device.

6. The device of claim 1 , wherein the spiral member is substantially planar.

7. The device of claim 1 , wherein the spiral member is a three-dimensional spiral.

8. The device of claim 1 , where the spiral member includes a shape memory material.

9. The device of claim 8 , where the shape memory material is nitinol.

10. The device of claim 1 , wherein the actuation system comprises a power source, a microcontroller, and an actuation mechanism configured to drive the plug and displace the at least one drug formulation from the reservoir by positive displacement.

Assignments (10)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 6, 2025
From: XEROX CORPORATION
To: GENESEE VALLEY INNOVATIONS, LLC
Reel/Frame 073842/0479 →
SECOND LIEN NOTES PATENT SECURITY AGREEMENT Recorded Jul 2, 2025
From: XEROX CORPORATION
To: U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 071785/0550 →
FIRST LIEN NOTES PATENT SECURITY AGREEMENT Recorded Apr 11, 2025
From: XEROX CORPORATION
To: U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS COLLATERAL AGENT
Reel/Frame 070824/0001 →
SECURITY INTEREST Recorded Feb 13, 2024
From: XEROX CORPORATION
To: CITIBANK, N.A., AS COLLATERAL AGENT
Reel/Frame 066741/0001 →
TERMINATION AND RELEASE OF SECURITY INTEREST IN PATENTS RECORDED AT RF 064760/0389 Recorded Feb 13, 2024
From: CITIBANK, N.A., AS COLLATERAL AGENT
To: XEROX CORPORATION
Reel/Frame 068261/0001 →
SECURITY INTEREST Recorded Nov 20, 2023
From: XEROX CORPORATION
To: JEFFERIES FINANCE LLC, AS COLLATERAL AGENT
Reel/Frame 065628/0019 →
CORRECTIVE ASSIGNMENT TO CORRECT THE REMOVAL OF US PATENTS 9356603, 10026651, 10626048 AND INCLUSION OF US PATENT 7167871 PREVIOUSLY RECORDED ON REEL 064038 FRAME 0001. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT. Recorded Jun 28, 2023
From: PALO ALTO RESEARCH CENTER INCORPORATED
To: XEROX CORPORATION
Reel/Frame 064161/0001 →
SECURITY INTEREST Recorded Jun 22, 2023
From: XEROX CORPORATION
To: CITIBANK, N.A., AS COLLATERAL AGENT
Reel/Frame 064760/0389 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 20, 2023
From: PALO ALTO RESEARCH CENTER INCORPORATED
To: XEROX CORPORATION
Reel/Frame 064038/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 15, 2013
From: JOHNSON, DAVID MATHEW; SHERIDAN, MARTIN; UHLAND, SCOTT A.; ABHISHEK, RAMKUMAR; PEETERS, ERIC; CURLEY, TIMOTHY J.; LINN, FELICIA; SCHMAELZLE, PHILIPP H.
To: PALO ALTO RESEARCH CENTER INCORPORATED
Reel/Frame 029634/0229 →